1145P - Efficacy of Somatostatin Analogs (SSA) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) according to ki67 index: A single centre experience

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Neuroendocrine Tumours
Supportive Measures
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Riccardo Marconcini
Citation Annals of Oncology (2014) 25 (suppl_4): iv394-iv405. 10.1093/annonc/mdu345
Authors R. Marconcini1, S. Ricci2, E. Vasile1, L. Galli1, A. Antonuzzo2, L. Derosa1, A. Farnesi1, E. Biasco1, E. Bracco1, R. Vaglialoro1, A. Sbrana1, A. Falcone1
  • 1U.o. Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria S.Chiara, 56100 - Pisa/IT
  • 2Oncologia, Trapianti E Nuove Tecnologie In Medicina, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, 56126 - Pisa/IT



PROMID and CLARINET studies showed antitumor activity associated with SSA, respectively Octreotide LAR (Oc) and Lanreotide LAR (La) in low grade GEP-NET. PROMID enrolled ki67 index <2% patients (pts), CLARINET enrolled ki 67index <10% pts. In this study we analyze our experience with Oc and La in metastatic GEP-NET, including those with ki67 index > 10%.


A retrospective analysis was conducted on 137 patients (pts) with advanced GEP-NETs treated upfront with Oc (30 mg 1 fl every 28 days) or La (120 mg 1 fl every 28 days) until disease progression: 87 gastrointestinal (GI) NET pts, 50 pancreatic (P) NET pts. Ki67 was specified in 89 pts and it was <3% in 38 pts, 3-5% in 15 pts, 5-10% in 15 pts, >10% in 21 pts. Toxicity was evaluated based on CTCAE v4.0, response according RECIST Criteria.


Median time from NET diagnosis and SSA treatment was 5,2 months (0,5 -1121months). Partial response was obtained in 12 pts (9%), stable disease in 112 pts (81%) and progressive disease in 13 pts (10%). In pts treated with Oc and La, median PFS was respectively 24.6 and 21.83 months. In GI NET pts and P NET pts, median PFS was respectively 21,73 and 24,73 months. In pts with ki67 index <2%, 2-5%, 5-10%, > 10%, median PFS was respectively 27.15, 34.77, 28.3, 20 months.


Oc and La showed comparable efficacy in terms of PFS in both PNET and GI NET, in all ki 67 index groups, suggesting that SSA treatment is efficacy also in ki 67 > 10% pts.


All authors have declared no conflicts of interest.